AC
KPTI icon

Armistice Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Armistice Capital’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-256,904
Closed -$13.1M – 242
2022
Q4 		$13.1M Buy
+256,904
New +$17.8M 0.23% 68

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armistice Capital's KPTI Position: Q1 2023 in Review

Armistice Capital sold out of Karyopharm Therapeutics (KPTI) in Q1 2023, closing a stake of 256,904 shares — an estimated $13.1M sold.

Armistice Capital first reported a position in KPTI in Q4 2022 and held it in 1 quarter. The position peaked at $13.1M in Q4 2022. 129 funds tracked by Wall St. Rank hold KPTI as of Q1 2023.

  • Armistice Capital reported no remaining Karyopharm Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Armistice Capital sold 256,904 Karyopharm Therapeutics shares in Q1 2023, an estimated $13.1M.
  • Armistice Capital first reported a position in Karyopharm Therapeutics in Q4 2022 and held it in 1 quarter.
  • Armistice Capital's Karyopharm Therapeutics position peaked at $13.1M in Q4 2022.
  • 129 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2023.

Based on Armistice Capital's 13F filing for Q1 2023, filed 15 May 2023.